AI-developed drug improves lung function in idiopathic pulmonary fibrosis
FierceBiotech - 12-Nov-2024Drug improved chronic cough symptoms, contributing to a better quality of life\
Insilico Medicine
Biotechnology company that uses artificial intelligence to develop new drugs and for aging research
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
Insilico Medicine Leadership
- Alex Zhavoronkov, PhD, Chairman of the Board, Executive Director & CEO
- Feng Ren, PhD, Executive Director, Co-CEO, Chief Scientific Officer
- Alex Aliper, President
- Michelle Chen, Chief Business Officer
- Sujata Rao, Chief Medical Officer
Insilico Medicine Scientific Advisory Board
- Charles Cantor
- Michael Levitt
- Kai-Fu Lee
- Alán Aspuru-Guzik
- Donald Small
- Klaus Witte
- Stevan Djuric
- Bud Mishra
Visit website: https://insilico.com/
Details last updated 09-Apr-2019
Mentioned in this Resource
Alex Zhavoronkov
CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation
Bud Mishra
Computer scientist and professor at the Courant Institute of Mathematical Sciences of New York University
Charles Cantor
Former Chief Scientific Officer at Sequenom and member of Scientific Advisory Board at Insilico Medicine
Kai-Fu Lee
Chairman and CEO at Sinovation Ventures and President at Sinovation Ventures Artificial Intelligence Institute
Insilico Medicine is also referenced in the following:
ARDD 2021 - 8th Aging Research and Drug Discovery Meeting
31-Aug-2021 to 03-Sep-2021
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
Deep Longevity
AI to track the rate of ageing at the molecular, cellular, tissue, organ, system, physiological, and psychological levels
Enabling AI-Guided End-to-End Drug Discovery - Alex Zhavoronkov at Longevity Summit Dublin 2024
Alex Zhavoronkov delivered a keynote on AI-Guided End-to-End Drug Discovery
Other people at Insilico Medicine
Polina Mamoshina
Chief Scientist and Chief Operating Officer at Deep Longevity and Head of Biomarker Development at Insilico Medicine.
Insilico Medicine News
Insilico's AI-designed drug proves effective in treating lung disease
Longevity Technology - 20-Sep-2024Phase 2a trial results show positive outcomes among pulmonary fibrosis patients
Insilico Medicine showcases 10 years of AI success in drug discovery
GEN - 01-Aug-2024AI could cut preclinical drug development time by half, but rigorous trials are crucial
Insilico reveals process for manufacturing AI-generated lung disease treatment
Chemical & Engineering News (C&EN) - 10-Mar-2024AI streamlines drug discovery, taking a potential treatment from concept to clinical trials in record time
AI and quantum computing join forces to crack the code of life
EurekAlert! - 26-Jan-2024This "physics-guided AI" approach promises deeper insights than current methods
Researchers used artificial intelligence to treat cancer and ageing
Drug Discovery World (DDW) - 16-Nov-2023KDM1A emerged as dual-action therapeutic target for both
SRW and Insilico partner to develop AI-powered nutraceuticals
Longevity Technology - 08-Nov-2023Using AI to screen natural compounds and create novel longevity products
Insilico Medicine identifies potential targets for ageing and disease using AI
EurekAlert! - 27-Sep-2023Highlights the potential of AI to accelerate drug discovery for several diseases
Insilico Medicine begins phase II trials for AI-generated drug candidate in IPF Treatment
Genetic Engineering & Biotechnology News (GEN) - 27-Jun-2023Could target the treatment of a broader range of fibrotic indications beyond idiopathic pulmonary fibrosis
BBC reports on two different uses of AI in pharmaceutical healthcare
BBC - 17-Apr-2023Genetika+ tests drugs against a patient's own cells; Insilico Medicine is slashing the time taken for drug discovery
Insilico Medicine series D funding to grow its pipeline and create an AI-driven robotic drug discovery laboratory
Longevity Technology - 06-Jun-2022Big data combined with laboratory automation - the pace of drug discovery is about to take off!
Insilico raises $255M to advance human trials and AI drug discovery platform
Longevity Technology - 22-Jun-2021New collab with Teva Pharmaceuticals to identify drug targets for various diseases
First-ever AI designed drug candidate for pulmonary fibrosis
Longevity Technology - 24-Feb-2021Insilico's novel drug target is prepping for IND studies, expecting to start clinical studies by early 2022
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021More and more companies making greater and greater progress - 2021 could be an exciting year
Pharma company teams with AI to develop anti aging solutions
Longevity Technology - 15-Oct-2020Taisho and Insilico collabs to identify novel targets for senolytic drugs
AI reduces drug discovery from years to days - and that's just the start
Singularity Hub - 23-Jul-2020Insilico Medicine is slashing the cost of drug development
Deep Longevity investors bet on growing need for aging and longevity biomarkers
FierceBiotech - 15-Jul-2020Biological clocks are a moving target so they'll need other researchers to corroborate their analysis
Is it possible to predict biological age with gut microbiome?
Lifespan.io (LEAF) - 19-Jun-2020Models and anti-ageing intervention design enables new ageing clock development
Orion College ageing research receives 1 million UK pounds from Jim Mellon
Lifespan.io (LEAF) - 18-May-2020He believes in the importance of boosting immunoresilience among elderly
Proposed strategy to protect elderly from gerolavic infections like COVID-19
Forbes - 31-Mar-2020To benefit long term global health and longevity, and enhance economic recovery
Clinical trials now up for Exscientia's world first AI-made drug
pharmaphorum - 30-Jan-2020Partnering with Japan's DSP, a milestone is reached in OCD treatment
Nanalyze looks at Insilico Medicine's AlphaGo moment in pharma
Nanalyze - 09-Oct-2019From lab to clinic in 2 years instead of 10 would have a huge impact on health
Insilico and ARK enter a research collaboration on health-span and longevity
EurekAlert! - 22-May-2019AI-based methods, to explore mechanisms of ageing and improving health-span
Gut microbiome predicts age with 4 year accuracy
Lifespan.io (LEAF) - 15-Jan-2019It both affects and is affected by its host status
Aging focused biotechs forms AI based joint venture
FierceBiotech - 14-Aug-2018Groundbreaking research biotechs performs aging research together for longevity
Interview with Juvenescence author Jim Mellon
Medium - 17-May-2018Juvenescence Ltd is making investments in the future of rejuvenation and life extension technology
AgeX Identifies Genes Implicated in Regeneration and Cancer
Business Wire - 02-Jan-2018Study that reveals genes implicated in tissue regeneration, cancer, and aging. Worked in collabo...
9 Computational Drug Discovery Startups Using AI
Nanalyze - 25-Apr-2017Including BenevolentAI which already has 24 drug candidates. 98% of big data has only been creat...
AI Versus Aging
Lifespan.io (LEAF) - 18-Apr-2017Interview with Dr. Alex Zhavoronkov, CEO of Insilico Medicine Company awarded the ‘Most Promisin...
Billionaire Jim Mellon invests in anti-ageing research firm
pharmaphorum - 11-Apr-2017Insilico Medicine applying big data analytics to extend healthy longevity. pursuing internal dru...
